News And Events

Press Releases

March 21, 2017
EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme

March 2, 2017
EnGeneIC Receives FDA Orphan Drug Designation for Targeted EDV™ Nanocells to Treat Glioblastoma Multiforme

October 9, 2016
EnGeneIC Enters Into Research Collaboration with Takeda to Develop EDV™-Based Immunomodulatory Therapies for Oncology

October 3, 2016
EnGeneIC’s Joint-CEO and Co-Founder, Jennifer MacDiarmid, Ph.D., Recognized in Innovation Category in The Australian Financial Review and Westpac 100 Women of Influence Awards for 2016

April 7, 2016
EnGeneIC Announces Publication of Late-Stage Canine Brain Cancer Study Results in PLOS ONE

April 6, 2016
EnGeneIC Ltd. to Present at BIO CEO & Investor Conference 2016.

March 10, 2016
EnGeneIC receives Science Meets Business Top 25 Australian R&D spin-off companies award.

January 25, 2016
EnGeneIC Ltd. Strengthens Board of Directors to Support U.S. Expansion

January 5, 2016
EnGeneIC Limited to Present at the 34th Annual J.P. Morgan Healthcare Conference

November 11, 2015
EnGeneIC Ltd. to Present at the Stifel 2015 Healthcare Conference

October 15, 2015
EnGeneIC Ltd. to Present at The 14th Annual BIO Investor Forum

September 16, 2015
EnGeneIC Ltd. to Initiate U.S. Phase 1 Clinical Study Using Targeted EDV™ Nanocells to Treat Advanced Glioma Patients

August 19, 2015
EnGeneIC Initiates Phase 1 Tailored-EDV Clinical Study in Solid Tumors

June 23, 2015
EnGeneIC Recognized as One of the Most Innovative Organizations in Australia at the 2015 Thomson Reuters Australian Citation & Innovation Awards

June 15, 2015
EnGeneIC and Asbestos Diseases Research Institute Announce Encouraging Results from MesomiR-1 Phase 1 Trial in Late Stage Mesothelioma patients

February 4, 2015
EnGeneIC to Present at BIO CEO & Investor Conference 2015

January 6, 2015
EnGeneIC Completes $10 Million Series B Financing Led by U.S. Institutional Investor

November 10, 2014
EnGeneIC and Asbestos Diseases Research Institute Initiate MesomiR-1 Phase 1 Trial in Patients with Late Stage Mesothelioma

September 15, 2014
EnGeneIC Named a Recipient of the Cancer Institute NSW Premier’s Award for Excellence in Translational Cancer Research

August 11, 2014
EnGeneIC Receives Patent from the USPTO for EDV™ Nanocell Technology

June 24, 2014
EnGeneIC Unveils Clinical Development Strategy for EDV™ Nanocell Technology